(Q42792127)

7 November 2017

Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models (English)

1 reference

7 November 2017

0 references

angiogenesis inhibitor

1 reference

Robert J D'Amato

1

1 reference

7 November 2017

Suzanne Lentzsch

series ordinal

2

1 reference

7 November 2017

Michael S Rogers

series ordinal

3

1 reference

7 November 2017

language of work or name

English

0 references

publication date

3 December 2013

1 reference

Proceedings of the National Academy of Sciences of the United States of America

7 November 2017

1 reference

7 November 2017

110

1 reference

7 November 2017

50

1 reference

7 November 2017

E4818

1 reference

Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864340

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864340

Identification of a primary target of thalidomide teratogenicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864340

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864340

27 May 2018

Identifiers

DOI

10.1073/PNAS.1315875110

1 reference

7 November 2017

0 references

1 reference

7 November 2017

PubMed publication ID

24302770

1 reference